<DOC>
	<DOCNO>NCT02971228</DOCNO>
	<brief_summary>The purpose study determine whether Bionic Pancreas ZP4207 ( dasiglucagon* ) feasible improve glycemic control adult type 1 diabetes mellitus . *dasiglucagon propose International Nonproprietary Name ( pINN ) ZP4207</brief_summary>
	<brief_title>Feasibility Trial Testing Bionic Pancreas With ZP4207</brief_title>
	<detailed_description>This single-center , open-label , 2-part , randomized cross-over trial . The trial enroll 20 adult patient type 1 diabetes mellitus assess safety efficacy Bionic Pancreas ( BP ) use either iLet iPhone platform use glucagon analogue ZP4207 ( dasiglucagon ) versus Lilly glucagon . In Part 1 , 10 patient participate two 1-day treatment arm random order ( iPhone-based BP use ZP4207 ( dasiglucagon ) iPhone-based BP use Lilly glucagon ) accord pre-generated randomization scheme . In Part 2 , 10 new patient participate two 1-day treatment arm random order ( iLet use ZP4207 ( dasiglucagon ) iLet use Lilly glucagon ) accord pre-generated randomization scheme . Patients participate 1 part trial . One day BP use glucagon analogue ZP4207 ( dasiglucagon ) day BP use Lilly glucagon . Subjects also receive insulin lispro BP day . The trial conduct single center , Massachusetts General Hospital Diabetes Center Boston , MA .</detailed_description>
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 1</mesh_term>
	<mesh_term>Insulin , Globin Zinc</mesh_term>
	<mesh_term>Insulin</mesh_term>
	<mesh_term>Insulin Lispro</mesh_term>
	<mesh_term>Glucagon</mesh_term>
	<mesh_term>Pancrelipase</mesh_term>
	<mesh_term>Pancreatin</mesh_term>
	<mesh_term>Glucagon-Like Peptide 1</mesh_term>
	<criteria>1 . Patients T1DM least 1 year , define American Diabetes Association 2 . Age ≥ 18 year 3 . Prescription medication regimen stable &gt; 1 month ( except medication expect affect trial safety outcome , judgment investigator ) 4 . Diabetes manage use insulin pump &gt; =6 month 5 . Patients good health accord age ( medical history , physical examination , vital sign , 12lead electrocardiogram [ ECGs ] , laboratory assessment ) , judge Investigator 1 . Previous exposure ZP4207 adverse reaction glucagon 2 . History liver disease current abnormal LFTs 3 . Renal failure 4 . Anemia 5 . History coronary artery disease congestive heart failure ( class III IV ) 6 . History transient ischemic attack stroke 7 . Seizure disorder 8 . Cystic fibrosis , pancreatitis , pancreatic disease besides T1DM 9 . Other endocrine disorder 10 . Use oral antidiabetic medication 11 . Electronically powered implant 12 . Hypertension ( ≥160/100 mm Hg despite treatment ) 13 . Inadequate venous ( vein ) access determine trial nurse physician time screen</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2016</verification_date>
	<keyword>glucagon</keyword>
	<keyword>T1DM</keyword>
	<keyword>Bionic Pancreas</keyword>
	<keyword>diabetes</keyword>
	<keyword>iLet</keyword>
	<keyword>iPhone</keyword>
	<keyword>Beta Bionics</keyword>
	<keyword>Anti-hypoglycemia</keyword>
	<keyword>Glucagon Analog</keyword>
</DOC>